<DOC>
	<DOCNO>NCT01194648</DOCNO>
	<brief_summary>RATIONALE : High-intensity focus ultrasound energy may able kill tumor cell heat without affect normal tissue . PURPOSE : This phase II trial study high-intensity focus ultrasound treat patient localized prostate cancer .</brief_summary>
	<brief_title>High-Intensity Focused Ultrasound Treating Patients With Localized Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine proportion men free prostate cancer treat area AND free clinically significant prostate cancer untreated area 36 month focal therapy use high-intensity focus ultrasound ( HIFU ) . - To determine proportion men free clinically significant prostate cancer treat untreated area 36 month focal therapy use HIFU . Secondary - To determine rate erectile dysfunction HIFU . - To determine time return erectile function HIFU . - To determine rate urinary incontinence HIFU . - To determine time return continence ( pad-free , leak-free , pad-free alone ) HIFU . - To determine rate loss ejaculation focal therapy use HIFU . - To determine rate loss orgasm . - To determine rate pain intercourse . - To determine rate significant decrease penile length HIFU . - To determine number men use phosphodiesterase-5 inhibitor maintain erectile function HIFU . - To determine rate low urinary tract symptom HIFU . - To determine rate bowel toxicity HIFU . - To determine anxiety level HIFU . - To determine general health-related quality life HIFU . - To determine histological outcome treat untreated area 12 month 36 month HIFU . - To determine proportion men achieve trifecta status ( i.e. , severe ED , pad-free leak-free continence , cancer control absence CS-PC ) 36 month HIFU . - To determine rate secondary prostate cancer intervention ( prostatectomy , radiotherapy , androgen ablation , whole-gland HIFU , cryosurgery ) HIFU . - To determine risk factor failure define presence cancer clinically significant cancer study end . - To analyze outcome parameter term biochemical ( PSA ) kinetics include determine optimal biochemical definition failure . - To describe composite outcome failure HIFU . - To determine cost treatment model potential cost effectiveness use comparative cancer control functional outcome 36 month compare cohort trial involve management localized prostate cancer . - To determine clinical validity ( sensitivity , specificity , negative positive predictive value , inter-observer variability [ MRI ] ) following : - Multi-parametric MRI predict presence clinically significant prostate cancer template transperineal prostate-mapping biopsy prior focal therapy . - MRI change predict presence residual/recurrent clinically significant prostate cancer biopsy . - HistoScanning™ predict presence clinically significant prostate cancer template transperineal prostate-mapping biopsy prior focal therapy . - HistoScanning™ predict presence residual/recurrent clinically significant prostate cancer biopsy . OUTLINE : This multicenter study . Patients undergo hemi-ablation high-intensity focus ultrasound ( HIFU ) ; treatment cover side gland clinically significant lesion ( ) identify combination MRI biopsy . Patients undergo multi-parametric MRI HistoScanning™ baseline 12 36 month , transrectal ultrasound biopsy baseline 12 month , template transperineal biopsy baseline 36 month . Patients complete questionnaire health-related quality life , urinary , erectile , bowel toxicity , anxiety level baseline periodically completion treatment . Financial data collect periodically determine cost-effectiveness treatment compare therapy . After completion study treatment , patient follow 6 week , 3 month , every 6 month 38 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer transrectal transperineal template prostate biopsy Transrectal ultrasound ( TRUS ) biopsy : burden bilateral disease maximum 3 mm one biopsy nondominant side allow Template biopsy follow : Unilateral disease burden Bilateral disease 1 following : Presence clinically significant cancer one side ( determined histological rule describe ) Gleason ≤ 7 Clinically insignificant disease burden &gt; 50 % biopsy core take side Bilateral clinically insignificant disease &lt; 50 % biopsy core positive one side dominant disease burden one side Low intermediaterisk disease , meet follow criterion : PSA &lt; 15 ng/mL Gleason score ≤ 4+3 T1T2c , N0 , M0 disease ( radiological T3a permit ) Untreated disease No presence prostatic calcification cyst ( TRUS ) whose location interfere effective delivery highintensity focal ultrasound ( HIFU ) therapy No evidence metastatic disease nodal disease outside prostate bone scan crosssectional imaging PATIENT CHARACTERISTICS : Must fit major surgery assess anesthesiologist Life expectancy ≥ 10 year Has understand English language sufficient understand write verbal information trial consent process Must able tolerate transrectal ultrasound ( TRUS ) Must able pelvic MRI scanning ( e.g. , severe claustrophobia , permanent cardiac pacemaker , metallic implant likely contribute significant artifact image ) No latex allergies No presence metal implants/stents urethra No renal impairment GFR &lt; 35 mL/min ( unable tolerate gadolinium dynamic contrastenhanced MRI ) PRIOR CONCURRENT THERAPY : No prior radiation therapy No androgen suppression/hormone treatment within past 12 month prostate cancer No prior significant rectal surgery prevent insertion transrectal HIFU probe ( decide type surgery individual case ) No prior HIFU , cryosurgery , thermal microwave therapy prostate More 6 month since prior transurethral resection prostate ( TURP ) manage low urinary tract symptom</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>urinary incontinence</keyword>
	<keyword>male erectile disorder</keyword>
	<keyword>therapy-related toxicity</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>